Clinical Trials
139 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Soundtrack-E
AstraZeneca
CAR-p40-T
Shenzhen University General Hospital
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Lumi-NHL
AstraZeneca
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Step Pharma, SAS
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
TranspoCART19
Instituto de Investigación Biomédica de Salamanca
OPAL
AVM Biotechnology Inc
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
ADAPT-HEM
Beijing Biotech
ZUMA-4
Gilead Sciences
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
National University Hospital, Singapore
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Nantong University
CAR/TRuC-T
Shenzhen University General Hospital
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
Atalanta-1
Lakefront Biotherapeutics NV
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
MK-4280-003
Merck Sharp & Dohme LLC
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
MSTH-CAR002
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NatHaLi-01
Cellectis S.A.
STARLIGHT-1
Estrella Immunopharma, Inc.
BAH241
Essen Biotech
CAR-T
Shenzhen University General Hospital
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Cancer Research UK
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd